Page 58 - AN-4-2

Advanced Neurology George Cotzias and L-DOPA therapy

doi: 10.1016/j.tips.2005.05.002 57. Poewe WH, Wenning GK. The natural history of Parkinson’s
disease. Ann Neurol. 1998;44:1-9.
45. Miranda M, Bustamante LM, Mena F, Lees A. Original
footage of the Chilean miners with Manganism published in 58. Rakshi, JS, Pavese N, Uema T, et al. A comparison of the
Neurology in 1967. Neurology. 2015;85:2166-2169. progression of early Parkinson’s disease in patients started
on ropinirole or L-dopa: An F-dopa PET study. J Neural
doi: 10.1212/WNL.0000000000002223
Transm (Vienna). 2002:109;1433-1443.
46. Altman KL, CeCotzias GB. Neurologist Who Developed
L‐DopaTherapy. New York Times; 1977. Available from: 59. Carlsson A. A half-century of neurotransmitter research:
https://www.nytimes.com/1977/06/14/archives/dr-george- Impact on neurology and psychiatry (Nobel Lecture).
c-cotzias-neurologist-whodeveloped-ldopa-therapy.html ChemBioChem. 2001;2:484-493.
[Last accessed on 2023 Mar 24]. doi: 10.1002/1439-7633(20010803)2:7/8<484:AID-
CBIC484>3.0.CO;2-5
47. Ovallath S, Sulthana B. L-DOPA: History and therapeutic
applications. Ann Indian Acad Neurol. 2017;20:185-189. 60. Mora PM, Mondragon-Hernandez C, Ramirez-Crespo M,
et al. Conventional and novel pharmacological approaches
doi: 10.4103/aian.AIAN_241_17
to treat dopamine-related disorders: Focus on Parkinson’s
48. Papavasiliou PS, Cotzias GC, Düby SE, et al. L-DOPA disease and schizophrenia. Neuroscience. 2019;19183:1-18.
in parkinsonism: Potentiation of central effects with a
peripheral inhibitor. N Engl J Med. 1972;285:8-14. doi: 10.1016/j.neuroscience.2019.07.026
61. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM.
doi: 10.1056/NEJM197201062860102
Treatment of parkinsonism with levodopa. Arch Neurol.
49. Stansley BJ, Yamamoto BK. Behavioral impairments 1969;21(4):343-354.
and serotonin reductions in rats after chronic L-DOPA. doi: 10.1001/archneur.1969.00480160015001
Psychopharmacology (Berl). 2015;232:3203-3213.
62. Cotzias GC, Papavasiliou PS, Tolosa ES, Mendez JS,
doi: 10.1007/s00213-015-3980-4
Bell-Midura M. Treatment of Parkinson’s disease with
50. Tren, G. Deep brain stimulation: A successor to L-DOPA? Aporphines. Possible role of growth hormone. N Engl J Med.
Berkeley Sci J. 2009;13(1):24-28. 1976;294:567-572.
doi: 10.5070/BS3131007613 doi: 10.1056/NEJM197603112941101
51. Velasco F, Velasco M. A quantitative evaluation of the effects 63. Frequin HL, Schouten J, Verschuur CVM, et al. L-DOPA
of l-dopa on Parkinson’s disease. Neuropharmacology. response in patients with early Parkinson disease:
1973;12:89-99. Further observations of the LEAP study. Neurology.
2023:100(4);e367-e376.
doi: 10.1016/0028-3908(73)90079-8
doi: 10.1212/WNL.0000000000201448
52. Hornykiewicz O. A brief history of L-DOPA. J Neurol.
2010;257:249-252. 64. Jost TS, Kaldenbach AM, Antonini A, et al. Levodopa dose
equivalency in Parkinson’s disease: Updated systematic
doi: 10.1007/s00415-010-5741-y
review and proposals. Mov Disord. 2023;38(7):1236-1252.
53. Papavasiliou PS, Miller ST, Cotzias GC, Kraner HW, Hsieh RS.
Sequential analysis: Manganese, catecholamines and l-dopa doi: 10.1002/mds.29410
induced dyskinesia. J Neurochem. 1975;25:215-219. 65. Sako W, Kogo Y, Koebis M, et al. Comparative efficacy
and safety of adjunctive drugs to levodopa for fluctuating
doi: 10.1111/j.1471-4159.1975.tb06955.x
Parkinson’s disease-network meta-analysis. NPJ Parkinson’s
54. Koller CW, Lyons EK, Truly W. Effect of L-DOPA treatment disease. 2023;9:143.
for parkinsonism in welders. Neurol. 2004;62:730-733.
doi: 10.1038/s41531-023-00589-8
doi: 10.1212/01.wnl.0000113726.34734.15
66. Verschuur MVC, Suwijn RS, Boel AJ, et al. Randomized
55. Björklund A, Dunnett BS. Fifty years of dopamine research. delayed-start trial of L-levodopa in Parkinson’s disease.
Trends Neurosci. 2007;30(5):185-187. N Engl J Med. 2019;380(4):315-324.
doi: 10.1016/j.tins.2007.03.004 doi: 10.1056/NEJMoa1809983
56. Foster HD, Hoffer A. The two faces of L-DOPA: Benefits and 67. Zhang Y, Meredith GE, Mendoza-Elias N, et al. Aberrant
adverse side effects in the treatment of Encephalitis lethargica, restoration of spines and their synapses in L-DOPA-
Parkinson’s disease, multiple sclerosis and amyotrophic lateral induced dyskinesia: Involvement of corticostriatal but not
sclerosis. Med Hypotheses. 2004;62:177-181. thalamostriatal synapses. J Neurosci. 2013;33:11655-11667.
doi: 10.1016/S0306-9877(03)00318-9 doi: 10.1523/JNEUROSCI.0288-13.2013

Volume 4 Issue 2 (2025) 52 doi: 10.36922/an.5177